Using liquid biopsies to guide treatment for pancreatic cancer
Part of Cancer clinical trials.
This study is testing a way to use blood samples, called liquid biopsies, to find tiny bits of cancer left after surgery and choose the best follow-up treatments for pancreatic cancer. It might help doctors personalize care for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- You are 18 years or older.
- You can understand and sign a consent form in Swedish.
- You are scheduled for surgery intended to remove all of the cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a blood test to find pancreatic cancer early. It may help people who are at risk or have suspicious signs.
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
This trial uses a liquid biopsy (a simple blood test that looks for cancer DNA) to decide whether you should have chemotherapy before surgery or go straight to surgery. It is for people with pancreatic cancer that has not spread beyond the pancreas.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.